Seaport Reports Positive GlyphAllo Driving Trial Results In Healthy Volunteers

Seaport Therapeutics reported positive Phase 1 results for GlyphAllo, showing no next-morning driving impairment at 250 mg after a single dose or 375 mg after multiple doses.